ClinicalTrials.gg
RecruitingNCT07260500Updated Feb 17, 2026

A Phase II Study of PEG-rhGH Injection for Short Children Born Small for Gestational Age: Efficacy, Safety, and Pharmacokinetics

A Phase 2 interventional study of PEG-rhGH Injection and hGH Injection in Short Stature Children Born Small for Gestational Age (SGA), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 3 Years and older. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
3 Years and older
Sex
All
01

Study summary

This study will take place at multiple sites and is divided into three phases:an initial 4-week getting-to-know-you phase,a 26-week main phase where participants receive medication,and a 4-week follow-up phase.Participants will be divided into three groups:two will receive different doses of PEG-rhGH Injection,and the third will receive hGH Injection.The goal is to determine which medication works best.

02

Conditions studied

  • Short Stature Children Born Small for Gestational Age (SGA)
03

In context

Lead sponsor

Changchun GeneScience Pharmaceutical Co., Ltd. is the lead sponsor of 112 studies on the registry; 47 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Born full-term and "small-for-dates" - Born at 37-41 weeks (full-term). - Birth weight below the 10th percentile for that week of pregnancy and sex .
  • At least 3 years old on the day the parent signs the consent form.
  • Still prepubertal (Tanner stage I - no signs of puberty yet).
  • Height at the first study visit is more than 2 standard deviations below the average for his or her age and sex.
  • Bone age on X-ray is no more than 1 year ahead of real age.
  • Never taken growth hormone, IGF-1, or any ghrelin-like medicine before.
  • Both the subject and their guardian are able to voluntarily sign the Form (ICF) and voluntarily cooperate in completing the trial according to the protocol. If the subject is legally incompetent, written informed consent from their guardian shall be obtained. Additionally, relevant information about the clinical trial shall be communicated to the subject within their understanding, and the subject should be encouraged to sign the ICF personally as much as possible.

Exclusion criteria

Exclusion Criteria:

  • Severe allergy to growth hormone or its ingredients.
  • Growth-hormone deficiency.
  • Any chromosome/genetic/syndrome cause of short stature.
  • Other diseases that can impair growth.
  • Cognitive, developmental, or psychiatric disorders that could affect assessments .
  • Current or past cancer, or high familial cancer risk.
  • Positive , , , or active tuberculosis at screening.
  • Abnormal liver or kidney blood tests.
  • Pre-diabetes or diabetes at screening .
  • Systemic > 28 consecutive days or > 14 days total in the last 3 months.
  • High-dose inhaled steroids > 28 days in the last year.
  • Prior use of aromatase inhibitors, GnRH analogues, sex hormones, anabolic agents, or other drugs that affect growth. 13. Unable to receive subcutaneous injections.
  • Claustrophobia or inability to undergo brain MRI.
  • Participated in another clinical trial with treatment within 3 months.
  • Any other condition that, in the investigator's opinion, makes the child unsuitable for the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    PEG-rhGH dose 1 weekly

    Jintrolong® dose 1, subcutaneous injection, once every week for 26 weeks.

    Drug: PEG-rhGH Injection

  • Experimental
    PEG-rhGH dose 2 weekly

    Jintrolong® dose 2, subcutaneous injection, once every week for 26 weeks

    Drug: PEG-rhGH Injection

  • Active comparator
    Daily hGH (active control)

    Jintropin® dose 3, subcutaneous injection, once daily for 26 weeks.

    Drug: hGH Injection

Interventions

  • DrugPEG-rhGH Injection

    Jintrolong® Dose 1, subcutaneous injection, once weekly for 26 weeks for 24 subjects.. Jintrolong® Dose 2, subcutaneous injection, once weekly for 26 weeks for 24 subjects..

    Also known as: Jintrolong®

  • DrughGH Injection

    Jintropin® dose 3, subcutaneous injection, once daily for 26 weeks (active comparator) for 24 subjects.

    Also known as: Jintropin®

06

What researchers measure

Primary outcomes

  1. Annual height velocity at Week 26 of treatment

    Time frame: 26 Weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2025
First posted
Dec 3, 2025
StartActual
Nov 11, 2025
Primary completionEst.
Dec 23, 2026
CompletionEst.
Apr 30, 2027
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07260500
Responsible party
Sponsor
First posted
Dec 3, 2025
Start date
Nov 11, 2025
Primary completion
Dec 23, 2026 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Feb 17, 2026

Study contacts

Xiao Ping Luo
Contact
xpluo888@sina.com
+8613387522645
Ling Hou
Contact
houlingtj@163.com
+8613437131846

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion